Get informed when a big investor buys or sells
+ FollowUndervalued by 68.1% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $82.86 Million |
|---|---|
| Enterprise Value | $82.86 Million |
| Earnings per Share | $-15.07 |
| Beta | 2.01 |
| Outstanding Shares | 2,734,013 |
| P/E Ratio | -1.99 |
|---|---|
| PEG | -1.59 |
| Price to Sales | 30.03 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 21.78 |
| Enterprise Value to EBIT | -2.46 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | - |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include Reducer, for the treatment of refractory angina, which is not current...
In the latest 13F quarter on Stockcircle, 1 top investor reduced or sold among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.
Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.